about
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several ne...
Read More
208.94
-3.62
(-1.70%)
3.0M
XNYS Volume
XNYS 08 Sep, 2025 3:24 PM (EDT)
Medium Financial Strength
Mid Valuation
Technically Moderately Bullish
Turnaround Potential
These stocks may be affordable or expensive due to their medium quality and a good technical scoring. However, their reasonable financials successfully attract investors.
View Similar
Embed DVM
AbbVie Live Price Chart
Switch to TradingView
Loading Fundamental data..
Loading data..